Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 2, 2006 Brian Gorman	Cambrex in a Crunch The drug manufacturer is suffering despite positive macro trends. For now, investors shouldn't expect much from Cambrex.
IndustryWeek March 1, 2008 David Blanchard	The Biggest Challenges Facing Manufacturers -- IndustryWeek's 2008 Salary Survey Responses Offshore competition. Finding and retaining skilled labor. Rising costs. Government regulations. Sound familiar? Manufacturing managers share many of the same headaches and confront common challenges.
The Motley Fool July 12, 2004 Brian Gorman	India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...
The Motley Fool September 28, 2004 Brian Gorman	Cambrex's Dose of Reality The biopharma's outlook is cloudy due to stiffer competition in biomanufacturing.
IndustryWeek March 1, 2009 David Blanchard	IndustryWeek's 2009 Salary Survey Comments on Manufacturing's Biggest Challenge: The Economy As part of the IndustryWeek 2009 Salary Survey, we asked the open-ended question: What is the biggest challenge facing the manufacturing industry today?
The Motley Fool May 5, 2004 Brian Gorman	Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas.
The Motley Fool December 15, 2004 Brian Gorman	Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies.
IndustryWeek March 1, 2007 David Blanchard	Manufacturing's Biggest Challenges -- IndustryWeek's 2007 Salary Survey Responses If you come to work everyday worrying about global competition, finding and keeping skilled labor, raw material shortages, and the quality of your product, you're not alone.
Job Journal September 21, 2003 Marty Nemko	Biotech = Opportunity What this strong growth industry could offer you
Entrepreneur November 2005 Nichole L. Torres	Closer Than You Think The internet has made it easier for startups to find information on overseas outsourcing. Just keep in mind, it's going to require some serious legwork. Here are some tips.
IndustryWeek November 1, 2002 Tonya Vinas	Questioning Biotech's Benefits While most communities are investing to attract or grow biotechnology companies, a recent report concludes that only a handful of cities will benefit in the long run.
IndustryWeek July 1, 2006	Outsourcing's Next Steps When it's best not to chase cheap labor.
The Motley Fool September 25, 2007 Billy Fisher	Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics.
Reason June 2004 Adrian Moore	Importing Affluence Democrats and Republicans are now engaged in a partisan Three Stooges slap fight over who is more outraged by offshore outsourcing.
Knowledge@Wharton	The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope...
The Motley Fool September 11, 2008 Brian Lawler	ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet.
The Motley Fool December 18, 2009 Brian Orelli	Buy a Company, Get the Plant for Free Earlier this year, Merck company bought a pipeline of follow-on biologics (and a manufacturing plant to make them in) from Insmed. Now it's back for more with an acquisition of Avecia Biologics.
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool January 4, 2007 Ralph Casale	Picks and Shovels of Biotechnology Biotech investors will continue to venture into the dark mines of burgeoning pharmaceutical firms. There is certainly gold to be found in some of them, just remember to invest in some of the hardware stores of biotechnology along the way.
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
Job Journal June 1, 2008 Alesia Benedict	Career Pros: Steering Clear of Offshore Outsourcing Jobs most likely to get shipped overseas, and how to avoid being left adrift.
CFO May 1, 2007 Randy Myers	Going Away The doubts that finance executives once had about offshoring are quickly disappearing as savings and process improvements become too good to pass up.
The Motley Fool October 26, 2010 Selena Maranjian	Make Money in Biotech the Simple Way These ETFs present an easy way to invest in biotechnology.
Pharmaceutical Executive September 1, 2008	How Do You Solve a Problem Like Manufacturing? Outsourcing saves pharmaceutical companies money -- except when it doesn't. Here's how to decide what to do.
BusinessWeek November 10, 2003 Arlene Weintraub	Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk
Chemistry World October 15, 2013 Emily James	Roche backs biologic boom The world's largest biotech company, Roche, has announced it will invest 800 million Swiss francs into manufacturing biological medicines over the next five years.
CIO September 1, 2003 Christopher Koch	Backlash As a growing number of IT jobs move overseas, some CIOs and economists prophesy a political storm against offshore outsourcing.
The Motley Fool April 29, 2009 Brian Orelli	Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising.
The Motley Fool November 2, 2009 Brian Orelli	Winners and Losers of the House Health-Care Reform Bill There's something for everyone to hate.
Bio-IT World June 15, 2003 Bob Violino	Mid-Atlantic/Southeast Region Maryland: Making a Federal Case for Biotechnology... Puerto Rico: Isle of Incentives... Virginia: Planting Needed Seed Capital... North Carolina: Triangulating Biotech Resources... Florida: Shining Resources on Small Biotech Sector
The Motley Fool August 21, 2008 Brian Lawler	PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
Bank Systems & Technology June 2, 2004 Cynthia Ramsaran	Outsourcing Obstacles Banks can save money with offshore outsourcing, but they need a plan to navigate the choppy waters.
The Motley Fool July 9, 2004 Selena Maranjian	Complexities of Offshore Outsourcing This is not a simple issue, and perhaps companies should not base the decision on whether to offshore jobs simply on expected cost savings. Instead, many other factors should be considered.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool January 28, 2011 Luke Timmerman	Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up.
Global Services June 1, 2008 Imrana Khan	Offshoring: Not the Answer to the Challenges of Globalization Offshore outsourcing enabled globalization and its economics brought value to the business. What now?
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
Inc. May 2006	America, At Your Service Globalization has been a boon for some U.S. service companies. Last year, a surplus of $58 billion in services was outsourced overseas. Here is a selection of recent data on cross-border trade from the Bureau of Economic Analysis.
Bio-IT World October 14, 2004 Robinson & Violino	Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape.
IndustryWeek March 1, 2008 David Blanchard	Manufacturing Is Not For the Faint at Heart -- IndustryWeek's 2008 Salary Survey Comments When asked to comment on the state of the industry, manufacturing managers throughout the United States share a common concern that the odds seem to be stacked against them.
The Motley Fool December 3, 2010 Travis Hoium	Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement.
Knowledge@Wharton March 26, 2003	Health Care Finance Industry Plagued by Lack of Funding, Focus In today's health care finance environment, early financing rounds are harder to fund and the market for initial public financings is dead, with no revival expected anytime soon.
Bio-IT World June 15, 2003 Bob Violino	Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
Bio-IT World November 19, 2004	Taking the Industry's Temperature 2005 will be a better year for Biotech from an economic viewpoint, and a fairly aggressive year for Biotech and BioPharma in terms of incorporating new technology into research, development, and manufacturing activities.
CFO December 1, 2006 Kate O'Sullivan	Biotech Dreaming Cities and states in the U.S. are vying to become biotechnology hot spots. Ultimately, some regions may not have enough of the key ingredients for biotech success.